29 October 2024
Incanthera
plc
("Incanthera" the
"Company")
Further re:
Commercial Update
Incanthera plc (AQSE:INC), the
company focused on innovative technologies in dermatology and
oncology, announces an update on its Skin + CELL luxury skincare
range.
Further to the Commercial Update of
26 September 2024, the Company undertook to update the market in
October regarding the timing of the European launch of Skin + CELL.
While the Company awaits clarity on timings, it remains
committed to updating the market with full details as soon as these
are available.
For further information please
contact:
Notes to Editors
About Incanthera plc
Incanthera is a specialist company
focused on innovative technologies in dermatology and
oncology. It seeks to identify and develop innovative solutions to
current clinical, commercially relevant unmet needs, utilising new
technology from leading specialists and academic institutions as
well as its in-house development team.
The Company originated from
the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford. Incanthera's strategy
is to develop each candidate in its portfolio from initial
acquisition or discovery to securing its future through
commercially valuable partnerships at the earliest opportunity in
its development pathway.
For more information on the Company
please visit: www.incanthera.com
@incantheraplc
About Skin + CELL
Skin + CELL is Incanthera's luxury
skincare brand utilising our ground-breaking formulation and
delivery expertise, to bring scientifically proven formulations to
cosmetics. Skin + CELL's complementary range of products are based
on advanced, clinically designed, formulation concentrates which
combine leading edge pharmaceutical enhancement technology with
selected prestige cosmetic ingredients to give an effective product
which gives a silky emollience in use and leaves the skin visibly
radiant, energised and protected.
Incanthera's new bioactive skincare
technology has been developed by our in-house experts who have
previously formulated topical products for some of the world's
leading skincare and pharmaceutical companies. The formulations
fortify otherwise depleted physiological pathways to improve the
skin's performance, ability to self-repair and to address
previously unmet cosmetic conditions in skin health.
Skin + CELL's luxury skincare
current range extends across face, body, hand, face serum and eye
cream, and will also include bioactive SPF concentrations and
further derivatives of vitamins in the future.
Forward looking statement
disclaimer
Certain statements made in this
announcement are forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the
Company's current expectations, estimates, and projections about
its industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements. The Company cautions shareholders
and prospective shareholders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this announcement. The forward-looking
statements made in this announcement relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.